Search Results - "Willemse, P H B"

Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands by de Munck, L., Schaapveld, M., Siesling, S., Wesseling, J., Voogd, A. C., Tjan-Heijnen, V. C. G., Otter, R., Willemse, P. H. B.

“…Trastuzumab in conjunction with adjuvant chemotherapy markedly improves outcome. In the Netherlands, a national guideline was released in September 2005…”
Get full text

The clinical trail of TRAIL by Duiker, E.W., Mom, C.H., de Jong, S., Willemse, P.H.B., Gietema, J.A., van der Zee, A.G.J., de Vries, E.G.E.

“…The naturally occurring tumour necrosis factor related apoptosis-inducing ligand (TRAIL) induces apoptosis through two death receptors, death receptor 4 (DR4)…”
Get full text

A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study by Reyners, A.K.L., de Munck, L., Erdkamp, F.L.G., Smit, W.M., Hoekman, K., Lalisang, R.I., de Graaf, H., Wymenga, A.N.M., Polee, M., Hollema, H., van Vugt, M.A.T.M., Schaapveld, M., Willemse, P.H.B.

“…In ovarian cancer, cyclooxygenase-2 (COX-2) overexpression is prognostic for poor survival. We investigated the efficacy of celecoxib (C), a selective COX-2…”
Get full text

Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy by Piccart, M J, Floquet, A, Scarfone, G, Willemse, P H B, Emerich, J, Vergote, I, Giurgea, L, Coens, C, Awada, A, Vermorken, J B

“…First-line intravenous chemotherapy (CT) following debulking surgery is associated with prolonged survival, in particular in patients who achieve a…”
Get more information

Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic–pharmacodynamic study by Joerger, M., Huitema, A. D. R., Huizing, M. T., Willemse, P. H. B., De Graeff, A., Rosing, H., Schellens, J. H. M., Beijnen, J. H., Vermorken, J. B.

“…What is already known about this subject • There are few data about the safety of paclitaxel in patients with clinically significant liver impairment. A study…”
Get full text

Long-term morbidity of adjuvant whole abdominal radiotherapy (WART) or chemotherapy for early stage ovarian cancer by Engelen, M.J.A, Snel, B.J, Schaapveld, M, Pras, E, de Vries, E.G.E, Gietema, J.A, van der Zee, A.G.J, Willemse, P.H.B

“…Abstract The aim of the study was to evaluate long-term toxicity of adjuvant treatment in early stage ovarian cancer survivors. Data from all patients treated…”
Get full text

Severe disabling tendinopathy caused by anastrazole by Martens, H. A., Schröder, C. P., van der Eerden, P. J. M., Willemse, P. H. B., Posthumus, M. D.

Get full text

The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium by Mourits, M J E, Hoor, K A Ten, van der Zee, A G J, Willemse, P H B, de Vries, E G E, Hollema, H

“…Aim: To study the effects of tamoxifen on the proliferation index and oestrogen receptor (ER) and progesterone receptor (PR) expression in postmenopausal…”
Get full text

Neuropsychological investigation into the carcinoid syndrome by RUSSO, S, NIELEN, M. M. A, BOON, J. C, KEMA, I. P, WILLEMSE, P. H. B, DE VRIES, E. G. E, KORF, J, DEN BOER, J. A

“…In patients suffering from metastatic carcinoid tumors, chronic disturbances of serotonergic metabolism are frequently present. Serotonin is supposed to…”
Get full text

Ovarian cysts in women receiving tamoxifen for breast cancer by MOURITS, M. J. E, DE VRIES, E. G. E, WILLEMSE, P. H. B, TEN HOOR, K. A, HOLLEMA, H, SLUITER, W. J, DE BRUIJN, H. W. A, VAN DER ZEE, A. G. J

“…Tamoxifen is a nonsteroidal anti-oestrogen with gynaecological side-effects. Only recently, ovarian cyst formation during tamoxifen treatment has been…”
Get full text

Granulosa cell tumors of the ovary: The clinical value of serum inhibin A and B levels in a large single center cohort by Mom, C.H, Engelen, M.J.A, Willemse, P.H.B, Gietema, J.A, ten Hoor, K.A, de Vries, E.G.E, van der Zee, A.G.J

“…Abstract Objectives. In patients with a granulosa cell tumor of the ovary, the value of serum inhibin A and B concentrations for the assessment of disease…”
Get full text

Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer by Maduro, J.H, Pras, E, Willemse, P.H.B, de Vries, E.G.E

“…Randomised studies in locally advanced cervical cancer patients showed that cisplatin should be given concurrently with radiotherapy, because of a better…”
Get full text

Guideline adherence for early breast cancer before and after introduction of the sentinel node biopsy by SCHAAPVELD, M, DE VRIES, E. G. E, OTTER, R, DE VRIES, J, DOLSMA, W. V, WILLEMSE, P. H. B

“…This population-based study aimed to analyse variations in surgical treatment and guideline compliance with respect to the application of radiotherapy and…”
Get full text

Debulking surgery for ovarian epithelial cancer performed by a gynaecological oncologist improved survival compared with less specialised surgeons by Engelen, M J A, van der Zee, A G J, de Vries, E G E, Willemse, P H B

Get full text

Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy: cardiovascular risk factors and signs of vascular damage by de Vos, F.Y.F.L., Nuver, J., Willemse, P.H.B., van der Zee, A.G.J., Messerschmidt, J., Burgerhof, J.G.M., de Vries, E.G.E., Gietema, J.A.

“…Male germ cell tumour patients treated with cisplatin-based chemotherapy frequently develop cardiovascular risk factors and disease, but sparse information is…”
Get full text

A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer by Bos, A.M.E., De Vos, F.Y.F.L., de Vries, E.G.E., Beijnen, J.H., Rosing, H., Mourits, M.J.E., van der Zee, A.G.J., Gietema, J.A., Willemse, P.H.B.

“…The aim of this study was to determine the maximum tolerated dose (MTD) of intraperitoneal (i.p.) topotecan combined with standard doses of intravenous (i.v.)…”
Get full text

Diagnostic, surgical and medical aspect of the midgut carcinoids by de Vries, H., Verschueren, R.C.J., Willemse, P.H.B., Kema, I.P., de Vries, E.G.E.

“…This review covers the incidence, prognosis, diagnosis and treatment of midgut carcinoids with emphasis on the surgical and peri-operative aspects. Midgut…”
Get full text

Review: Breast Cancer in Elderly Patients by DE GRAAF, H., WILLEMSE, P. H. B., SLEIJFER, D. TH

“…Breast cancer is the most common malignancy in older women, and the disease's incidence in that population is likely to increase. Physicians must make sure…”
Get full text

Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin by DE JONG, R. S, MULDER, N. H, UGES, D. R. A, SLEIJFER, D. T, HÖPPENER, F. J. P, GROEN, H. J. M, WILLEMSE, P. H. B, VAN DER GRAAF, W. T. A, DE VRIES, E. G. E

“…We conducted a phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin. Fostriecin was administered intravenously over 60 min…”
Get full text

Paclitaxel and Carboplatin Concurrent with Radiotherapy for Primary Cervical Cancer by DE VOS, F. Y. F. L, BOS, A. M. E, GIETEMA, J. A, PRAS, E, VAN DER ZEE, A. G. J, DE VRIES, E. G. E, WILLEMSE, P. H. B

“…Background: Concurrent radiochemotherapy is currently considered the new standard treatment in locally advanced cervical cancer. Patients and Methods: Eight…”
Get full text